Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
GSK offers pilots a Chantix alternative
Exploiting a competitor's weakness is a time-honored tradition in business. So it's probably no surprise that GlaxoSmithKline is injecting itself into the Chantix upheaval. You'll recall that last week the FAA told pilots and air traffic controllers they can't use the stop-smoking drug because of new links to accidents, dizziness, and other side effects. (Chantix's potential to cause psychiatric effects is already on the books.) Well, just before the holiday weekend, GSK offered its own stop-smoking product, Commit nicotine lozenges, to pilots and controllers for free. "It seemed to make sense to us to step up and offer this," Bill Slivka, VP for smoking control at GSK's consumer health unit, told the WSJ Health Blog.
- see the item at the Health Blog
Related Articles:
Chantix side-effects news prompts FAA ban
Chantix scrips drop 5% on FDA alert
FDA: Chantix may pose psych risks
FDA gets 5,000 Chantix complaints
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


